SavedAdd your journal

Journals / Nöropsikiyatri Arşivi / 2017 / Cilt: 54 - Sayı: 1

Metabolic Effects of Antidepressant Treatment

Antidepresan Tedavinin Metabolik Etkileri

Özlem EKER OLGUNER
SALİHA DEMİREL-ÖZSOY
Baki EKER
Hatice DOĞAN
Pages
49–56
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Insulin level and HOMA index had a

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: This study aimed to investigate body measurements, glucose-insulin metabolism, and lipid profile in patients with anxiety and depressive symptoms and also the effects of antidepressant drugs on these metabolic parameters.
📊
Key Findings & Data:Methods: The study included 40 outpatients and 32 healthy controls.
💡
Conclusion & Impact:Insulin level and HOMA index had a
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: This study aimed to investigate body measurements, glucose-insulin metabolism, and lipid profile in patients with anxiety and depressive symptoms and also the effects of antidepressant drugs on these metabolic parameters. Methods: The study included 40 outpatients and 32 healthy controls. The patients received antidepressant treatment (sertraline, escitalopram, fluoxetine, and venlafaxine) for 8 weeks. Body measurements were performed, and lipid, fasting blood glucose, and insulin levels were measured before and after treatment in patients and once in healthy controls. Insulin resistance was evaluated using the homeostasis model assessment (HOMA) index.Results: Body mass index was higher in patients than in healthy controls, and there was no change in patients after treatment. In patients, high-density lipoprotein (HDL) cholesterol levels increased owing to the antidepressant treatment. Insulin level and HOMA index had a

Özet

Amaç: Bu çalışmada anksiyete ve depresif belirtileri olan hastalarda vücut ölçümleri, glukoz-insülin mekanizması ve lipid profilinin araştırılması ve antidepresanların bu metabolik parametreler üzerine etkisinin araştırılması planlanmıştır

🔖

Cite This Article

OLGUNER, Ö. E., DEMİREL-ÖZSOY, S., EKER, B., DOĞAN, H. (2017). Metabolic Effects of Antidepressant Treatment. Nöropsikiyatri Arşivi, Cilt: 54 - Sayı: 1, 49–56. https://ajindex.com/articles/292276

References (11)

  1. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24:412-424
  2. Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190:S39-42
  3. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115-1121
  4. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32
  5. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 2009; 36:341-350
  6. Brady KT. Weight gain associated with psychotropic drugs. South Med J 1989; 82:611-617
  7. Muir-Cochrane E. Medical co-morbidity risk factors and barriers to care for people with schizophrenia. J Psychiatr Ment Health Nurs 2006; 13:447-452
  8. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61:1356-1370
  9. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26:137-141
  10. Cantu T, Korek J. Monoamine oxidase inhibitors and weight gain. Ann Pharmacother 1988; 22:755-759
  11. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47:411-418 12. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001; 62:256-260. 13